AstraZeneca PLC AstraZeneca prices a EUR800m bond offering (0100A)
May 27 2021 - 2:00AM
UK Regulatory
TIDMAZN
RNS Number : 0100A
AstraZeneca PLC
27 May 2021
27 May 2021 07:00 BST
AstraZeneca prices a EUR800m bond offering
AstraZeneca PLC ("AstraZeneca") announces that, on 26 May 2021,
it successfully priced EUR800m ($1bn equivalent) of fixed rate
notes with a coupon of 0.375%, maturing on 3 June 2029 (the
"Notes").
The Notes will be subject to special mandatory redemption if the
acquisition of Alexion Pharmaceuticals, Inc. ("Alexion") (the
"Alexion Acquisition") is not consummated on or before 12 March
2022 or, if prior to such date, AstraZeneca notifies the trustee
that AstraZeneca will not pursue the consummation of the Alexion
Acquisition.
AstraZeneca expects to use the net proceeds of the offering to
fund a portion of the purchase price for the Alexion Acquisition,
to pay or refinance a portion of Alexion's indebtedness and to pay
related fees and expenses, or for general corporate purposes.
The Notes will be issued under the $10,000,000,000 EMTN
programme of AstraZeneca and AstraZeneca Finance LLC, which
AstraZeneca filed with the UK Financial Conduct Authority on 24 May
2021, and admitted to listing on the UK Financial Conduct
Authority's Official List and to trading on the London Stock
Exchange's Main Market.
The Notes have not been registered under the U.S. Securities Act
of 1933 and may not be offered or sold in the United States absent
registration or an applicable exemption from registration.
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the Notes described herein, nor
shall there be any sale of these Notes in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction.
The issuance of the Notes does not impact AstraZeneca's
financial guidance for 2021.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines in
Oncology and BioPharmaceuticals, including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca operates in over 100 countries, and its
innovative medicines are used by millions of patients
worldwide.
AstraZeneca contacts
For details on how to contact the Investor Relations Team,
please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IODDZGZKKNGGMZG
(END) Dow Jones Newswires
May 27, 2021 02:00 ET (06:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024